This project has been flagged by a community member as inappropriate due to reason below.*

Survey

Slingshot members are conducting a survey! The topic is:

Quarterly Survey: Bradycardia and Implantable Pacemakers July 2023

Ticker(s): MDT, ABT, BSX

Who's being surveyed?

Survey results include 20 Cardiologists.

Survey Questions
Q1.

How many patients with bradycardia do you see on average each month?

Q2.

How many of your bradycardia patients do you consider eligible for an implantable pacemaker?

Q3.

What is the total number of bradycardia patients that currently use an implantable pacemaker?

Q4.

How many pacemaker implant surgeries have you performed in the last 30 days?

Q5.

How many pacemaker implant surgeries do you anticipate performing in the next 30 days?

Q6.

What is the percentage breakdown of implantable pacemaker device brands you currently use? Please specify between 0-100 for each.

  • Micra AV/Micra VR (Medtronic) 
  •  Azure (Medtronic) 
  •  Assurity MRI (Abbott) 
  •  Aveir VR (Abbott) 
  •  Accolade MRI (Boston Scientific) 
  •  Essentio MRI (Boston Scientific) 
  •  Edora (Biotronik) 
  •  Other

Q7.

How often do you consider cost in your implantable pacemaker brand decision? Select one.

Q8.

Which brand of implantable pacemaker device do you prefer most? Select one.

  • Micra AV/Micra VR (Medtronic)
  •  Azure (Medtronic)
  •  Assurity MRI (Abbott)
  •  Aveir VR (Abbott)
  •  Accolade MRI (Boston Scientific)
  •  Essentio MRI (Boston Scientific)
  •  Edora (Biotronik)
  •  Other

Q9.

Regarding the previous answer, why do you prefer the implantable pacemaker brand you selected? Please be specific.

Q10.

What features being added to future generations of implantable pacemakers would have you consider switching manufacturers or significantly shifting share? Please be specific.

Are You Interested In These Questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.